Portal hypertension and its complications

Current Opinion in Gastroenterology

Volumn 23, Issue 3, 2007, Pages 275-282

  Blei, Andres T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Ascites; Cirrhosis; Hepatic encephalopathy; Portal hypertension

Indexed keywords

ALDOSTERONE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENOIC ACID; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLONIDINE; CORTICOSTEROID; DIURETIC AGENT; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ISOSORBIDE MONONITRATE; NADOLOL; NORADRENALIN; NORFLOXACIN; RENIN; SPIRONOLACTONE; TERLIPRESSIN;

ADRENAL INSUFFICIENCY; ASCITES; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; CLINICAL TRIAL; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOSCOPIC THERAPY; ENDOTHELIAL DYSFUNCTION; ESOPHAGUS VARICES; GYNECOMASTIA; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HISTOPATHOLOGY; HUMAN; HYPONATREMIA; LABORATORY TEST; LIVER CIRRHOSIS; LUNG CAPILLARY PRESSURE; LUNG DISEASE; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; THROMBOCYTE COUNT; VENOUS PRESSURE;

ANTIHYPERTENSIVE AGENTS; ASCITES; HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; HYPONATREMIA; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; SCLEROTHERAPY;

EID: 34147102421     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3280b0841f     Document Type: Review

References (58)

1. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: the patient to the molecule. Hepatology 2006; 43 (Suppl 1):S121-S131. •• A review article that highlights common elements in the pathophysiology of all complications of portal hypertension.
2. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44:874-880.
3. Rockey DC, Bissel DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43 (Suppl 1):S113-S120. A 'state-of-the-art' review on the pressing search for alternatives to liver biopsy.
4. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55:403-408. • This relatively simple-to-use device holds promise as a screening tool for the diagnosis of cirrhosis.
5. Kazemi F, Kettaneh A, N'kontchou G, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45:230-235.
6. Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis: a histological classification of the severity of cirrhosis. J Hepatol 2006; 44:111-117.
7. Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol 2006; 44:209-216.
8. Matei V, Rodriguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006; 44:44-52. • This article highlights the reduction of intrahepatic vascular resistance as a therapeutic target in portal hypertension. Currently, nitrates are used with this objective, but tolerability of these drugs is not optimal. The dose of ascorbic acid was high (3 g) and was administered on a single occasion. More data are needed before recommending this approach.
9. Hernandez-Guerra M, Garcia-Pagan JC, Turnes J, et al. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology 2006; 43:485-491. • This article highlights the reduction of intrahepatic vascular resistance as a therapeutic target in portal hypertension. Currently, nitrates are used with this objective, but tolerability of these drugs is not optimal. The dose of ascorbic acid was high (3 g) and was administered on a single occasion. More data are needed before recommending this approach.
10. Hennenberg M, Biecker E, Trebicka J, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006; 130:838-854.
11. Tripathi D, Therapondos G, Ferguson JW, et al. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 2006; 55:1290-1295.
12. Sanyal AJ, Fontana RJ, Di Bisceglie AM, et al. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis Cand advanced fibrosis. Gastrointest Endosc 2006; 64:855-864.
13. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43:492-499. • Measurements of portal pressure via hepatic vein catheterization provide useful information in a wide variety of clinical conditions. The technique is available in most centers but used sparingly in the US for clinical decision-making, even though the data support a wider use.
14. Stokkeland K, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. Hepatology 2006; 43:500-505.
15. Turnes J, Hernandez-Guerra M, Abraldes JG, et al. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology 2006; 43:34-41.
16. Berzigotti A, Rinaldi MF, Magalotti D, et al. Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. J Hepatol 2006; 44:310-316.
17. Romero G, Kravetz D, Argonz J, et al. Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. Aliment Pharmacol Ther 2006; 24:601-611.
18. Tan PC, Hou MC, Lin HC, et al. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology 2006; 43:690-697; Erratum 43:1410. •• 'Super-glue' may be especially useful for large fundal varices, when banding is not only ineffective but may actually be dangerous.
19. Henderson JM, Boyer TD, Kutner MH, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology 2006; 130:1643-1651. • Most trials of TIPS have compared the stent versus endoscopic therapy. A major accomplishment is the completion of this trial, showing similar effectiveness of shunt surgery to the radiological approach. Shunting is a useful option for patients with good liver function.
20. Cowgill SM, Carey E, Villadolid D, et al. Preshunt liver function remains the prominent determinant of survival after portasystemic shunting. Am J Surg 2006; 192:617-621.
21. Kochar N, Tripathi D, Ireland H, et al. Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut 2006; 55:1617-1623. • Reduction, not occlusion, of the TIPS should be considered for such patients.
22. Senzolo M, Tibbals J, Cholongitas E, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006; 23:767-775. • Though technically challenging, the procedure could be completed in 75% of patients.
23. Fontana RJ, Sanyal AJ, Mehta S, et al. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol 2006; 101:983-992.
24. Sarin SK, Sollano JD, Chawla YK, et al. Consensus on extra-hepatic portal vein obstruction. Liver Int 2006; 26:512-519.
25. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130:2031-2038. • This paper points out a useful test in patients with hepatic and portal vein thrombosis, when myeloproliferative disease can be difficult to diagnose. The mutation also gives fascinating new insights into the pathogenesis of these disorders.
26. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44:1528-1534. • This paper points out a useful test in patients with hepatic and portal vein thrombosis, when myeloproliferative disease can be difficult to diagnose. The mutation also gives fascinating new insights into the pathogenesis of these disorders.
27. Thiesson HC, Jensen BL, Bistrup C, et al. Renal sodium retention in cirrhotic rats depends on glucocorticoid-mediated activation of mineralocorticoid receptor due to decreased renal 11beta-HSD-2 activity. Am J Physiol Regul Integr Comp Physiol 2006; 292:R625-R636.
28. Frey FJ. Impaired 11 beta-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: hypothesis or fact? Hepatology 2006; 44:795-801. • A novel pathogenic mechanism is proposed to explain sodium retention in cirrhosis. Bile acids may be responsible for the reduced β-HSD-2 activity in the kidney, a molecular mechanism that may partly explain old clinical observations of deleterious effects of bile acids on renal function.
29. Natarajan SK, Basivireddy J, Ramachandran A, et al. Renal damage in experimentally-induced cirrhosis in rats: role of oxygen free radicals. Hepatology 2006; 43:1248-1256.
30. Esteva-Font C, Baccaro ME, Fernandez-Llama P, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology 2006; 44:1555-1563.
31. Angeli P, Wong F, Watson H,Gines P, CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006; 44:1535-1542.
32. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130:1652-1660.
33. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099-2112. • The first of many trials focusing on the use of aquaretic agents to treat hyponatremia. For patients with cirrhosis and ascites, they may not only correct hyponatremia, but may also allow a safer andmore effective action of diuretics. The results of trials in liver disease are eagerly awaited.
34. Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4:1385-1394.
35. Bolondi L, Piscaglia F, Gatta A, et al. Effect of potassium canrenoate, an antialdosterone agent, on incidence of ascites and variceal progression in cirrhosis. Clin Gastroenterol Hepatol 2006; 4:1395-1402.
36. Lenaerts A, Codden T, Meunier JC, et al. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology 2006; 44:844-849. • The use of clonidine in patients with cirrhosis may result in lowering of the arterial pressure. In this study, blood pressure normalized with continuous use of the drug and resulted in greater effectiveness of spironolactone. Additional data are needed to indicate the safety and effectiveness of this approach over a longer period of administration, but the idea is novel and worthy of further study.
37. Sanyal A, Boyer T, Garcia-Tsao G, et al. A prospective, randomized, doubleblind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Hepatology 2006; 44:694A.
38. Singh V, Kumar B, Nain CK, et al. Noradrenaline and albumin in paracentesisinduced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006; 260:62-68.
39. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006; 43:385-394. • Terlipressin, noradrenaline and the combination of midodrine-octreotide-albumin have been used to treat hepatorenal syndrome type 1: newer indications could be envisioned based on the goal of reversing vasodilatation.
40. Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2006; 4:CD004889.
41. Natarajan SK, Ramamoorthy P, Thomas S, et al. Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: changes in glycosylation and luminal bacteria. Hepatology 2006; 43:837-846. • This article examines in the experimental animal different aspects of the pathogenesis as well as possible treatment of bacterial translocation in cirrhosis. This area has emerged as a critical initial step in the pathogenesis of many of the complications of portal hypertension.
42. Lorenzo-Zuniga V, Rodriguez-Ortigosa CM, Bartoli R, et al. Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut 2006; 55:1306-1312. • This article examines in the experimental animal different aspects of the pathogenesis as well as possible treatment of bacterial translocation in cirrhosis. This area has emerged as a critical initial step in the pathogenesis of many of the complications of portal hypertension.
43. Guarner C, Gonzalez-Navajas JM, Sanchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006; 44:633-639. • This article examines in the experimental animal different aspects of the pathogenesis as well as possible treatment of bacterial translocation in cirrhosis. This area has emerged as a critical initial step in the pathogenesis of many of the complications of portal hypertension.
44. Shaw E, Castellote J, Santin M, et al. Clinical features and outcome of spontaneous bacterial peritonitis in HIV-infected cirrhotic patients: a casecontrol study. Eur J Clin Microbiol Infect Dis 2006; 25:291-298.
45. Angeli P, Guarda S, Fasolato S, et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006; 23:75-84.
46. Fernandez J, Ruiz del Arbol L, Gomez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131:1049-1056.
47. Fernandez J, Escorsell A, Zabalza M, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006; 44:1288-1295. • This article describes adrenal insufficiency in these critically ill subjects, suggesting survival benefit from the administration of hydrocortisone.
48. Tsai MH, Peng YS, Chen YC, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 2006; 43:673-681. • This article describes adrenal insufficiency in these critically ill subjects.
49. Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 2006; 55:98-104.
50. Haussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2006; 43:1187-1190.
51. Kale RA, Gupta RK, Saraswat VA, et al. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 2006; 43:698-706. • Brain edema permeates the entire spectrum of liver failure, from life-threatening intracranial hypertension in acute liver failure to changes in water content in cirrhosis detected with sophisticated magnetic resonance techniques.
52. Minguez B, Garcia-Pagan JC, Bosch J, et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology 2006; 43:707-714.
53. Mack CL, Zelko FA, Lokar J, et al. Surgically restoring portal blood flow to the liver in children with primary extrahepatic portal vein thrombosis improves fluid neurocognitive ability. Pediatrics 2006; 117:e405-e412.
54. Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2006; 42:1158-1165. • Large portal-systemic shunts should be sought in patients with good liver function who exhibit repeated episodes of hepatic encephalopathy. They may be amenable to radiological closure.
55. Gomez FP, Barbera JA, Roca J, et al. Effects of nebulized N(G)-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology 2006; 43:1084-1091.
56. Fuhrmann V, Madl C, Mueller C, et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology 2006; 131:69-75.57
57. Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44:1502-1510. • In one-third of patients, 'high-output' heart failure, also termed cirrhotic cardiomyopathy, may explain an elevated pulmonary artery pressure. The pathogenesis of portopulmonary hypertension has still not been unraveled, although endothelin and vascular remodeling have emerged as potential mechanisms.
58. Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130:120-126.